Trial Profile

Safety & Efficacy of Genakumab in Patients With Frequent Flares

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Firsekibart (Primary) ; Betamethasone dipropionate/betamethasone sodium phosphate
Indications Gouty arthritis
Focus Registrational; Therapeutic Use
Acronyms GUARD-1
Sponsors GeneScience Pharmaceuticals

Most Recent Events

07 May 2026 According to a GeneScience Pharmaceuticals media release, company has received approval from National Medical Products Administration (NMPA). It is indicated for gouty arthritis (GA) treatment in adult patients for whom NSAIDs and/or colchicine are contraindicated, not tolerated, or ineffective and for whom repeated courses of corticosteroids are not suitable.
08 Nov 2024 Status changed from recruiting to completed.
11 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com